Glia biology of brain diseases
The aim of our research is to understand the role of glia in various brain diseases, such as Alzheimer’s disease and glioma, and to study the regenerative potential of the astrocytic stem cells in brain diseases.
Glial cells consist of astrocytes, microglia and oligodendrocytes, and are the most predominant cell type in the brain. Glia regulate local microcirculation, modulate the communication between neurons, and are the stem cells in the brain. Over the years, it has become increasingly clear that glia are involved in many brain diseases. Astrocytes can become reactive, which is likely to affect brain functioning. We use various techniques and model systems to unravel the molecular and functional changes in glia and how this contributes to the pathology of various brain diseases. The ultimate goal of our research is to contribute to developing therapeutic strategies to control reactive gliosis and to stimulate the endogenous repair capacity of the astrocytic stem cells in brain diseases.
Cognitive decline can also be the result of a stroke. Aneurysmal subarachnoid hemorrhage (SAH) is a bleeding into the subarachnoid space caused by a rupture of an intracranial arterial aneurysm. Aneurysmal SAH represents 5% of all stroke types and affects about 9 per 100,000 individuals annually. SAH occurs at a young age; half of the patients are younger than 50. The prognosis is poor as about a third of the patients will die within the first weeks, and another third will remain permanently disabled. We are studying the role of Subarachnoid Hemorrhage (SAH)-induced gliosis on cognitive impairment and a potential new therapeutic approach to promote recovery of brain function after SAH.
Overproliferation of neural stem cells can result in glioma. Gliomas are the most common form of malignant primary brain tumours in adults. A treatment remains to be found, which is mostly due to the highly invasive nature of these type of tumours. It is therefore important to decipher the mechanism of the cellular behaviour of glioma tumours. We study how the intermediate filament (IF) network, specifically the IF protein glial fibrillary acidic protein (GFAP), is involved in the cellular behaviour of glioma cells. Using a 3D model, we study the GFAP isoforms and how they influence the proliferative growth and invasiveness of patient-derived glioblastoma cells in organotypic brain slices.
It has also recently become clear that the protein IkappaBzetta plays an important role in the development of the most severe type of glioma, glioblastoma (GBM). Since patients with this type of brain tumor often don’t have a good prognosis, it is important to clarify the underlying mechanism. We aim to understand the molecular mechanism of the IkappaBzetta pathway in patient-derived GBM cell lines. We also intend to unravel if certain modulators can be controlled in a targeted manner, which could be used as novel targets for possible anti-tumour treatments.
Another focus is the interaction between GBM and its micro-environment. We make use of 2D co-culture models using primary patient tumor cells and tumor-derived immune cells, and a 3D patient-derived glioblastoma invasion model using cerebral organoids. By promoting the anti-tumour resonse of immune cells through overexpression of Class II Transactivator, the master regulator of MHC class II, we aim to better understand the role of the immune system in GBM and hopefully also have a possible target to be able to control GBM.
Mutant GFAP accumulates into astrocytic, cytoplasmic aggregates called Rosenthal fibers (RFs), leading to astrocyte dysfunction, activated microglia and subsequent white matter deterioration. How RFs are generated, why they are toxic and how astrocyte dysfunction leads to white matter pathology remains largely unknown. Moreover, mutant GFAP expressed in radial glial cells might cause neurogenesis defects. Animal models do not fully recapitulate AxD pathology, and human brain development cannot be fully modeled using animal models. Using patient iPSC-derived cerebral organoids, we aim to address these issues.
Our research also focusses on genetic risk factors in late-onset Alzheimer’s disease (AD), for which we use patient-derived iPSCs. The biggest risk factor lies within the apolipoprotein E (APOE) gene. The ApoE protein is highly expressed in astrocytes and upregulated in activated microglia, and is involved in Aβ clearance and cholesterol metabolism. We study the effect of APOE genotype on astrocyte-neuron interactions in a completely human model with human induced pluripotent stem cells (iPSC) from AD patients. In 2D co-cultures from human iPSC-derived neurons and astrocytes, we look at the neuronal network activity, astrocyte signaling and the tripartite synapse, whereas iPSC-derived brain organoids will shed light on the cellular 3D environment. With these approaches, we aim to increase our understanding of cellular mechanisms underlying AD and how the APOE genotype is involved.
Lab coordinator and assistance with molecular- and cell biological experiments
Cell culture, viral production, human postmortem brain tissue, MACSorting, molecular cloning, PCR and Q-PCR, immunohistochemistry, genotyping, Bio-IP, westernblot
Helping around in the lab with data analysis and other lab work.
Genotyping, data analysis, microscopy
My ambition is to decipher the molecular mechanisms that promote or impair neural stem cells to regenerate the mammalian brain to ultimately stimulate successful regeneration of the human brain.
Mouse injury models, post-mortem human brain tissue, (single-cell) omics, fate-mapping, high resolution imaging
Investigating the role of intermediate filaments, more specifically the role of glial fibrillary acidic protein (GFAP) splice variants, in glioma invasion and proliferation.
CRISPR-Cas9 gene editing, ex vivo brain slice invasion model, whole-mount immunohistochemistry
Unravelling alterations in synaptic plasticity and neuron-glia interactions in early-stage Alzheimer’s disease.
Slice electrophysiology, calcium imaging, immunohistochemistry
I am fascinated by the interaction of glioblastoma and its micro-environment. In particular, I focus on promoting the anti-tumor response of immune cells through overexpression of Class II Transactivator, the master regulator of MHC class II.
2D co-culture models using primary patient tumor cells and tumor-derived immune cells, 3D patient-derived glioblastoma invasion model using cerebral organoids
Investigating the role of Subarachnoid Hemorrhage (SAH)-induced gliosis on cognitive impairment and a potential new therapeutic approach.
Mouse models for SAH, high resolution imaging
My research focusses on the effect of APOE4, the largest genetic risk factor for late onset AD, on neuron-glia interaction in iPSC models.
2D human iPSC models, human brain organoids, glia, calcium imaging
Examining the role of astrocytes in Alzheimer’s disease by making use of a mouse model. Determining the differences between Alzheimer’s disease astrocytes and healthy controls, and testing whether changes in astrocyte gene expression can rescue memory deficits as observed in our mouse model.
Immunohistochemistry, MACSorting, sequencing, mouse breeding, memory tasks
Modeling Alexander Disease with cerebral organoids
iPSC culture, generation and analysis of cerebral organoids
My research focusses on the cellular and functional mapping of the human Ventral Tegmental Area in order to provide a single cell reference atlas to understand the involvement of cell types in reward system-related brain disorders.
Nuclei isolation, RNA sequencing, single cell-omics, 2D and 3D immunohistochemistry, human post-mortem brain tissue
The future may tell, by culturing cancer cells in a dish, we unravel glioma as our wish: understanding the oncogenic role of IkappaBzetta in glioblastoma, and targeting as a therapy.
Western Blot, PCR, ELISA, cell transfection, immuno-assays
- van Bodegraven EJ, Sluijs JA, Tan AK, Robe PAJT, Hol EM. New GFAP splice isoform (GFAPµ) differentially expressed in glioma translates into 21 kDa N-terminal GFAP protein. FASEB J. 2021 Mar;35(3):e21389. doi: 10.1096/fj.202001767R. PMID: 33583081.
- Smit T, Deshayes NAC, Borchelt DR, Kamphuis W, Middeldorp J, Hol EM. Reactive astrocytes as treatment targets in Alzheimer’s disease-Systematic review of studies using the APPswePS1dE9 mouse model. Glia. 2021 Feb 25. doi: 10.1002/glia.23981. Epub ahead of print. PMID: 33634529.
- Escartin C, Galea E, Lakatos A, O’Callaghan JP, Petzold GC, Serrano-Pozo A, Steinhäuser C, Volterra A, Carmignoto G, Agarwal A, Allen NJ, Araque A, Barbeito L, Barzilai A, Bergles DE, Bonvento G, Butt AM, Chen WT, Cohen-Salmon M, Cunningham C, Deneen B, De Strooper B, Díaz-Castro B, Farina C, Freeman M, Gallo V, Goldman JE, Goldman SA, Götz M, Gutiérrez A, Haydon PG, Heiland DH, Hol EM, Holt MG, Iino M, Kastanenka KV, Kettenmann H, Khakh BS, Koizumi S, Lee CJ, Liddelow SA, MacVicar BA, Magistretti P, Messing A, Mishra A, Molofsky AV, Murai KK, Norris CM, Okada S, Oliet SHR, Oliveira JF, Panatier A, Parpura V, Pekna M, Pekny M, Pellerin L, Perea G, Pérez-Nievas BG, Pfrieger FW, Poskanzer KE, Quintana FJ, Ransohoff RM, Riquelme-Perez M, Robel S, Rose CR, Rothstein JD, Rouach N, Rowitch DH, Semyanov A, Sirko S, Sontheimer H, Swanson RA, Vitorica J, Wanner IB, Wood LB, Wu J, Zheng B, Zimmer ER, Zorec R, Sofroniew MV, Verkhratsky A. Reactive astrocyte nomenclature, definitions, and future directions. Nat Neurosci. 2021 Mar;24(3):312-325. doi: 10.1038/s41593-020-00783-4. Epub 2021 Feb 15. PMID: 33589835; PMCID: PMC8007081.
- Verkerke M, Hol EM, Middeldorp J. Physiological and Pathological Ageing of Astrocytes in the Human Brain. Neurochem Res. 2021 Feb 8. doi: 10.1007/s11064-021-03256-7. Epub ahead of print. PMID: 33559106.
- Snijders GJLJ, van Zuiden W, Sneeboer MAM, Berdenis van Berlekom A, van der Geest AT, Schnieder T, MacIntyre DJ, Hol EM, Kahn RS, de Witte LD. A loss of mature microglial markers without immune activation in schizophrenia. Glia. 2021 May;69(5):1251-1267. doi: 10.1002/glia.23962. Epub 2021 Jan 7. PMID: 33410555; PMCID: PMC7986895.
- Alsema AM, Jiang Q, Kracht L, Gerrits E, Dubbelaar ML, Miedema A, Brouwer N, Hol EM, Middeldorp J, van Dijk R, Woodbury M, Wachter A, Xi S, Möller T, Biber KP, Kooistra SM, Boddeke EWGM, Eggen BJL. Profiling Microglia From Alzheimer’s Disease Donors and Non-demented Elderly in Acute Human Postmortem Cortical Tissue. Front Mol Neurosci. 2020 Oct 28;13:134. doi: 10.3389/fnmol.2020.00134. PMID: 33192286; PMCID: PMC7655794.
- Antonovaite N, Hulshof LA, Hol EM, Wadman WJ, Iannuzzi D. Viscoelastic mapping of mouse brain tissue: Relation to structure and age. J Mech Behav Biomed Mater. 2021 Jan;113:104159. doi: 10.1016/j.jmbbm.2020.104159. Epub 2020 Oct 28. PMID: 33137655.
- de Sonnaville SFAM, van Strien ME, Middeldorp J, Sluijs JA, van den Berge SA, Moeton M, Donega V, van Berkel A, Deering T, De Filippis L, Vescovi AL, Aronica E, Glass R, van de Berg WDJ, Swaab DF, Robe PA, Hol EM. The adult human subventricular zone: partial ependymal coverage and proliferative capacity of cerebrospinal fluid. Brain Commun. 2020 Oct 13;2(2):fcaa150. doi: 10.1093/braincomms/fcaa150. PMID: 33376983; PMCID: PMC7750937.
- Snijders GJLJ, Sneeboer MAM, Fernández-Andreu A, Udine E; Psychiatric donor program of the Netherlands Brain Bank (NBB-Psy), Boks MP, Ormel PR, van Berlekom AB, van Mierlo HC, Bӧttcher C, Priller J, Raj T, Hol EM, Kahn RS, de Witte LD. Distinct non-inflammatory signature of microglia in post-mortem brain tissue of patients with major depressive disorder. Mol Psychiatry. 2020 Oct 7. doi: 10.1038/s41380-020-00896-z. Epub ahead of print. PMID: 33028963.
- Fernandez-Klett F, Brandt L, Fernández-Zapata C, Abuelnor B, Middeldorp J, Sluijs JA, Curtis M, Faull R, Harris LW, Bahn S, Hol EM, Priller J. Denser brain capillary network with preserved pericytes in Alzheimer’s disease. Brain Pathol. 2020 Nov;30(6):1071-1086. doi: 10.1111/bpa.12897. Epub 2020 Sep 29. PMID: 32876357.